In a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin ( ERN ) alone , ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant ( ERN-L ) or placebo , niacin lowered serum phosphorus ; however , it is not known if it lowers FGF23 concentrations .